Recent Advancements in Nanocarrier-assisted Brain Delivery of Phytochemicals Against Neurological Diseases
Abstract Despite ongoing advancements in research, the inability of therapeutics to cross the blood–brain barrier (BBB) makes the treatment of neurological disorders (NDs) a challenging task, offering only partial symptomatic relief. Various adverse effects associated with existing approaches are another significant barrier that prompts the usage of structurally diverse phytochemicals as preventive/therapeutic lead against NDs in preclinical and clinical settings. Despite numerous beneficial properties, phytochemicals suffer from poor pharmacokinetic profile which limits their pharmacological activity and necessitates the utility of nanotechnology for efficient drug delivery. Nanocarriers have been shown to be proficient carriers that can enhance drug delivery, bioavailability, biocompatibility, and stability of phytochemicals. We, thus, conducted a meticulous literature survey using several electronic databases to gather relevant studies in order to provide a comprehensive summary about the use of nanocarriers in delivering phytochemicals as a treatment approach for NDs. Additionally, the review highlights the mechanisms of drug transport of nanocarriers across the BBB and explores their potential future applications in this emerging field..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Neurochemical research - 48(2023), 10 vom: 06. Juni, Seite 2936-2968 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mishra, Keerti [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Blood–brain barrier |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11064-023-03955-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052940535 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052940535 | ||
| 003 | DE-627 | ||
| 005 | 20230901064720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230901s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11064-023-03955-3 |2 doi | |
| 035 | |a (DE-627)SPR052940535 | ||
| 035 | |a (SPR)s11064-023-03955-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mishra, Keerti |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent Advancements in Nanocarrier-assisted Brain Delivery of Phytochemicals Against Neurological Diseases |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Despite ongoing advancements in research, the inability of therapeutics to cross the blood–brain barrier (BBB) makes the treatment of neurological disorders (NDs) a challenging task, offering only partial symptomatic relief. Various adverse effects associated with existing approaches are another significant barrier that prompts the usage of structurally diverse phytochemicals as preventive/therapeutic lead against NDs in preclinical and clinical settings. Despite numerous beneficial properties, phytochemicals suffer from poor pharmacokinetic profile which limits their pharmacological activity and necessitates the utility of nanotechnology for efficient drug delivery. Nanocarriers have been shown to be proficient carriers that can enhance drug delivery, bioavailability, biocompatibility, and stability of phytochemicals. We, thus, conducted a meticulous literature survey using several electronic databases to gather relevant studies in order to provide a comprehensive summary about the use of nanocarriers in delivering phytochemicals as a treatment approach for NDs. Additionally, the review highlights the mechanisms of drug transport of nanocarriers across the BBB and explores their potential future applications in this emerging field. | ||
| 650 | 4 | |a Neurodegenerative diseases |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Brain delivery |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Blood–brain barrier |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Phytochemicals |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nanotechnology |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nanocarriers |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Rana, Rafquat |4 aut | |
| 700 | 1 | |a Tripathi, Shourya |4 aut | |
| 700 | 1 | |a Siddiqui, Shumaila |4 aut | |
| 700 | 1 | |a Yadav, Pavan K. |4 aut | |
| 700 | 1 | |a Yadav, Prem N. |4 aut | |
| 700 | 1 | |a Chourasia, Manish K. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurochemical research |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1976 |g 48(2023), 10 vom: 06. Juni, Seite 2936-2968 |w (DE-627)SPR016233697 |w (DE-600)2018503-0 |x 1573-6903 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2023 |g number:10 |g day:06 |g month:06 |g pages:2936-2968 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11064-023-03955-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2023 |e 10 |b 06 |c 06 |h 2936-2968 | ||